

Title	Development of a highly specific and potent bi-functional antibody-drug conjugate for treatment of triple-negative breast cancer
--------------	--

Keywords	Breast Cancer, Antibody-Drug Conjugate, Drug Delivery
-----------------	---

Summary	<p>Breast cancer is the most common cancer in women, and the second most frequent cause of cancer related deaths in women worldwide. Approximately 15-20% of all breast cancers are referred to as triple-negative breast cancer (TNBC) due to a lack of three proteins: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Compared to other types of breast cancer, TNBC is highly invasive and metastatic, and rapidly progressive. Due to the lack of ER, PR and HER2 receptors, TNBC patients do not benefit from hormonal or anti-HER2 therapies. Therefore, radiation therapy and chemotherapy are currently the major treatment options for TNBC patients. However, these treatments provide a partial response with early relapse, worse prognosis and present severe adverse effects. Thus, in the present PhD proposal we will explore a novel class of antibody therapeutics, named “Smart-Bomb” Antibody-Drug Conjugates, to develop a more targeted, effective and safe treatment option for TNBC.</p>
----------------	--

Supervision	
Supervisor	Frederico Aires da Silva (CIISA, FMV-UL) fasilva@fmv.ulisboa.pt
Co-Supervisor	João Gonçalves (iMED, FFUL)
Co-Supervisor	João Nuno Moreira (CNC, FFUC)